CTI Clinical Trial and Consulting Services Acquires Multispecialty Research Site
CTI Clinical Trial and Consulting Services has acquired a multispeciality research site with three locations throughout Greater Cincinnati, Ohio.
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization has acquired a multispeciality research site with three locations throughout Greater Cincinnati, Ohio.
Community Research conducts 40-60 Phase I-IV clinical trials annually in a variety of therapeutic indications, including internal medicine, dermatology, psychiatry, and sleep disorders, as well as trials in healthy volunteers. Community Research operates a hospital-based, residential Phase I facility. The organization has conducted over 650 clinical trials since its formation 20 years ago.
You can read the full release here.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
